Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): A patent review (2008-present)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 7, 2012, Pages 803-841

  Lamers, Christina ^a   Schubert Zsilavecz, Manfred ^a   Merk, Daniel ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Cancer; CS 7017; Dyslipidemia; Fibrates; GW 501516; GW 590735; Hyperglycemia; Inflammatory diseases; Nuclear receptor modulators; Nuclear receptors; PAM 1616; PAR 1622; PAR 5359; Skin disorders; Thiazolidindiones

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; CS 7017; EXCELSIDE A; FATTY ACID AMIDE DERIVATIVE; GLITAZONE DERIVATIVE; IMMUNOLOGIC AGENT; INDOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; PAM 1616; PAR 1622; PAR 5359; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PROTEIN INHIBITOR; PUERARIN; PYRIMIDINONE DERIVATIVE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SR 1644; SR 1664; SR 1824; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADDICTION; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; AUTOIMMUNE DISEASE; BINDING AFFINITY; CARDIOVASCULAR DISEASE; DEGENERATIVE DISEASE; DIABETES MELLITUS; DRUG INDICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; INFLAMMATORY DISEASE; METABOLIC DISORDER; MUSCLE ATROPHY; NEOPLASM; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATENT; PROTEIN PHOSPHORYLATION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SKIN DISEASE; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIGANDS; METABOLIC DISEASES; PATENTS AS TOPIC; PPAR ALPHA; PPAR DELTA; PPAR GAMMA;

EID: 84862858211     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.699042     Document Type: Review

References (126)

1. Merk D, Schubert-Zsilavecz M. Nuclear receptors as pharmaceutical targets: Rise of FXR and rebirth of PPAR? Future Med Chem 2012;4(5):587-8
2. Crunkhorn S. Diabetes: Safer PPARgamma-targeted drugs on the horizon? Nat Rev Drug Discov 2011;10(11):814
3. Choi JH, Banks AS, Kamenecka TM, et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature 2011;477(7365):477-81
4. Berger J, Moller DE. the mechanisms of action of PPARs. Annu Rev Med 2002;53:409-35
5. Michalik L, Wahli W. Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta BBAMol Cell Biol Lipids 2007;1771(8):991-8
6. Schmuth M, Jiang YJ, Dubrac S, et al. Thematic review series: Skin Lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res 2008;49(3):499-509
7. Neher MD, Weckbach S, Huber-Lang MS, Stahel PF. New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury. PPAR Res 2012;2012:728461
8. Peters JM, Shah YM, Gonzalez FJ. the role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer 2012;12(3):181-95
9. Gronemeyer H, Gustafsson J, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004;3(11):950-64
10. Zettl H, Steri R, Lammerhofer M, Schubert-Zsilavecz M. Discovery of a novel class of 2-mercaptohexanoic acid derivatives as highly active PPARalpha agonists. Bioorg Med Chem Lett 2009;19(15):4421-6
11. Giaginis C, Theocharis S, Tsantili-Kakoulidou A. Structural basis for the design of PPAR-gamma ligands: A survey on quantitative structureactivity relationships. Mini Rev Med Chem 2009;9(9):1075-83
12. Gelman L, Feige J, Desvergne B. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes. Biochim Biophys Acta BBAMol Cell Biol Lipids 2007;1771(8):1094-107
13. Miyachi H. Design, synthesis, and structure-activity relationship study of peroxisome proliferator-activated receptor (PPAR) delta-selective ligands. Curr Med Chem 2007;14(22):2335-43
14. Feldman PL, Lambert MH, Henke BR. PPAR modulators and PPAR pan agonists for metabolic diseases: The next generation of drugs targeting peroxisome proliferator-activated receptors? Curr Top Med Chem 2008;8(9):728-49
15. Bayer Healthcare AG. 4-Phenoxy-nicotine acid derivatives and use thereof as PPAR-modulators: WO2008031500A1; 2008
16. Bayer Schering Pharma Aktiengesellschaft. 4-Phenoxy-nicotine acid derivatives and use thereof as PPAR-modulators: US20100160386A1; 2010
17. Aryx Therapeutics, Inc. Agonist of peroxisome proliferator activated receptor alpha: WO2010071813A1; 2010
18. Smithkline Beecham Corp. Carboxyl substituted indoles for use as PPAR alpha modulators: WO2009147121A1; 2009
19. Fundacion Instituto Mediterraneo para el Avance de la Biotecnologia y la Investigacion Sanitaria (IMABIS). Pyrazole derivatives of fatty acid amides as PPAR-alpha specific activators, preparation method thereof and use of same: WO2009050318A1; 2009
20. Fundacion Instituto Mediterraneo para el Avance de la Biotecnologia y la Investigacion Sanitaria (IMABIS). Fatty acid amide derivatives with amphetamines for the treatment of eating disorders: WO2011076966A1; 2011
21. Janssen Pharmaceutica NV. Drug combinations comprising a DGAT inhibitor and a PPAR-agonist: WO2009147170A2; 2009
22. He K. Extract of fraxinus excelsior seeds and therapeutic applications therefor: US20090117214A1; 2009
23. Wang H. Isoflavone glycosides as peroxisome proliferator-activated receptor-alpha modulator: US20090099099A1; 2009
24. Neopharm Co., Ltd. Use of PPAR alpha activator as inflammatory skin disease-treating agent and method for treating skin diseases using the same: US20100173995A1; 2010
25. Johns Hopkins University. Phase 2 inducers and related signaling pathways protect cartilage against inflammation/infection, apoptosis and stress: US20100015085A1; 2010
26. Carmeliet P. Use of PPAR alpha agonists to treat skeletal muscle wasting disorders: WO2008006819A2; 2008
27. Carmeliet P. Use of PPAR alpha agonists to treat skeletal muscle wasting disorders: US20090234150A1; 2009
28. Ghent University. Compositions and methods relating to glucocorticoid receptor alpha and peroxisome proliferator-activated receptors: US20090111782A1; 2009
29. Daiichi Sankyo Co., Ltd. Aryl derivatives: WO2008126731A1; 2008
30. Daiichi Sankyo Co., Ltd. Fused bicyclic heteroaryl derivatives: EP2138484A1; 2009
31. Daiichi Sankyo Co., Ltd. Pyridine derivative: EP2404918A1; 2012
32. Merck & Co., Inc. Novel crystalline salt form of an antidiabetic compound: WO2008109334A1; 2008
33. Merck & Co., Inc. Method of treatment using fused aromatic compounds having anti-diabetic activity: WO2008137105A1; 2008
34. Merck & Co., Inc. Antidiabetic azaindoles and diazaindoles: WO2009005672A1; 2009
35. Dong-A Pharm. Co., Ltd. Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same and pharmaceutical composition comprising the same: WO2008108602A1; 2008
36. Moon H-S. Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same and pharmaceutical composition comprising the same: US20100063041A1; 2010
37. Kim M, Chae YN, Choi S, et al. PAM-1616, a selective peroxisome proliferator-activated receptor gamma modulator with preserved anti-diabetic efficacy and reduced adverse effects. Eur J Pharmacol 2011;650(2-3):673-81
38. Kim M, Chae YN, Kim HS, et al. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention. Arch Pharm Res 2009;32(5):721-7
39. Kim M, Chae YN, Son MH, et al. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo. Eur J Pharmacol 2008;595(1-3):119-25
40. Evolva SA. Substituted 1,3-dioxanes useful as PPAR modulators: WO2008089461A1; 2008
41. Evolva SA. PPAR modulators: US20110178112A1; 2011
42. Smithkline Beecham Corp. 1H-Indole-2-carboxylic acid derivatives useful as PPAR modulators: WO2008028118A1; 2008
43. Kowa Co., Ltd. Novel compounds comprising a 3-(5-alkoxypyrimidin-2-yl)- pyrimidin-4(3H)-one structure and drugs that comprise same: US20110306623A1; 2011
44. Kowa Co., Ltd. Novel 1-(biphenyl-4-ylmethyl)-1H-imidazole derivative and pharmaceutical product containing same: WO2011077712A1; 2011
45. Kowa Co., Ltd. Novel 2-pyridone derivative and pharmaceutical product containing same: WO2011077711A1; 2011
46. Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds: EP1988091A1; 2008
47. Kyowa Hakko Kirin Co., Ltd. Tricyclic compounds: EP2327690A1; 2011
48. Kaneka Corp. Peroxisome proliferator-activated receptor ligand: US20080132544A1; 2008
49. Vivacell Biotechnology Espana, S.L. Cannabinoid quinone derivatives: WO2011117429A1; 2011
50. Shenzhen Neptunus Pharmaceutical Co., Ltd. Diphenylethene derivatives and uses thereof: WO2011075935A1; 2011
51. Epax AS. Composition comprising a PPAR agonist and a phospholipid component: WO2010039040A1; 2010
52. Epax AS. Composition comprising at least one PPAR agonist and a lipid component: US20100081694A1; 2010
53. Boehringer Ingelheim International GmbH. Pharmaceutical composition comprising an SGLT2 inhibitor and a PPAR-gamma agonist and uses thereof: WO2011120923A1; 2011
54. Theracos, Inc. Therapeutic uses of SGLT2 inhibitors: US20110077212A1; 2011
55. Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Composition useful for the prevention of adverse effects due to the use of PPAR-gamma agonists: WO2008141897A1; 2008
56. Dana-Farber Cancer Institute, Inc. Compositions, kits and methods for identification, assessment, prevention and therapy of metabolic disorders: WO2011091134A2; 2011
57. Rivier M, Castiel I, Safonova I, et al. Peroxisome proliferator-activated receptor-alpha enhances lipid metabolism in a skin equivalent model. J Invest Dermatol 2000;114(4):681-7
58. Galderma Research & Development. Novel biaromatic compounds that modulate PPAR-receptors: US20090012129A1; 2009
59. Galderma Research & Development. Novel 3-phenyl acrylic acid compound activators of type PPAR receptors and pharmaceutical/cosmetic compositions comprised thereof: US20100144884A1; 2010
60. Galderma Research & Development. Novel derivatives of 3-phenyl propanoic acid activating PPAR-type receptors, method for preparing same and use thereof in cosmetic or pharmaceutical compositions: WO2008152333A2; 2008
61. Galderma Research & Development. Novel 3-phenylpropanpoic compound activators receptors of PPAR type and pharmaceutical/cosmetic compositions comprised thereof: US20100158843A1; 2010
62. Umbert Millet, Ignacio. Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same: EP2311454A2; 2011
63. Umbert Millet, Ignacio. Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same: WO2009153373A2; 2009
64. Umbert Millet, Ignacio. Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same: US20110129546A1; 2011
65. Johnson and Johnson Consumer Companies, Inc. A composition comprising a PPAR-gamma agonist and method of treating facial skin defect: EP2123248A1; 2009
66. Avon Products, Inc. Use of eclipta prostrata and other PPAR-gamma inhibitors in cosmetics and compositions thereof: US20110305781A1; 2011
67. Rheinische Friedrich-Wilhelms Universitat. PPAR-gamma agonisten zur Behandlung von Erkrankungen mit pathophysiologischer Beteiligung von TH17-Lymphozyten: EP2301539A1; 2011
68. Peyrin-Biroulet L, Beisner J, Wang G, et al. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA 2010;107(19):8772-7
69. Giuliani International, Ltd. PPAR-gamma agonists for the induction of cationic antimicrobial peptide expression as immunoprotective stimulants: WO2008104557A1; 2008
70. Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based cohort study. Diabetologia 2012;55(7):1953-62
71. Cedars-Sinai Medical Center. Methods of using PPAR-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer: US20090264483A1; 2009
72. Shimazaki N, Togashi N, Hanai M, et al. Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. Eur J Cancer 2008;44(12):1734-43
73. Daiichi Sankyo Co., Ltd. Crystal of thiazolidinedione compound and process for production thereof: EP2311834A1; 2011
74. Daiichi Sankyo Co., Ltd. Crystal of thiazolidinedione compound and process for production thereof: EP2305673A1; 2011
75. Daiichi Sankyo Co., Ltd. Crystal of thiazolidinedione compound and process for production thereof: WO2010013769A1; 2010
76. Daiichi Sankyo Co., Ltd. Crystalline forms of thiazolidinedione derivative and its manufacturing method: WO2008099944A1; 2008
77. Daiichi Sankyo Co., Ltd. Crystal of thiazolidinedione compound and process for production thereof: WO2010013768A1; 2010
78. Soluciones Extractivas Alimentarias, S.L. Solutex. Docosahexaenoic acid ethyl esters and/or its derivatives for prevention and/or treatment of age-related macular degeneration: WO2011095837A1; 2011
79. Omeros Corp. Compositions and methods for prophylaxis and treatment of addictions: WO2010105103A1; 2010
80. Ciccocioppo R. Compositions and methods for prophylaxis and treatment of addictions: WO2008128126A1; 2008
81. Rhode Island Hospital. Treatment, prevention and reversal of alcohol-induced brain disease: US20100055037A1; 2010
82. Rhode Island Hospital. Treatment, prevention and reversal of alcohol-induced brain disease: US20100021386A1; 2010
83. Sanofi-Aventis. 6-Oxazol-4-ylmetholmethoxy-alko-alkoxymethyl substituted benzoic acid derivatives forming peroxisome proliferator activated receptor (PPAR) ligands, process for their preparation and methods of use thereof: US20080171776A1; 2008
84. the University of Sidney. Flavonoid PPAR agonists: WO2009026657A1; 2009
85. Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator activated receptor: WO2008016175A1; 2008
86. Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator activated receptor: WO2009128558A1; 2009
87. Glaxo Group Ltd. Thiazole and oxazole derivatives and their pharmaceutical use: WO002001000603; 2001
88. Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor delta: US20090298896A1; 2009
89. Nippon Chemiphar Co., Ltd. Activating agent of peroxisome proliferator activated receptor delta: US000007119104B2; 2000
90. Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator activated receptor: US20100029949A1; 2010
91. Smithkline Beecham Corp. Chemical compounds: WO2005077926A2; 2005
92. Nippon Chemiphar Co., Ltd. Activator agent for peroxisome proliferator activated receptor: US20110090098480A1; 2011
93. Nippon Chemiphar Co., Ltd., Cerenis Therapeutics S.A. Use of PPAR delta ligands for the treatment of prevention of inflammation or energy metanolism/production related diseases: US20110092517A1; 2011
94. Zhejiang Hisun Pharmaceutical Co., Ltd. Compound with agitation effect on peroxisome proliferator-activated receptor delta, and preparation method and use thereof: US20110319458A1; 2011
95. Novo Nordisk A/S. Novel compounds, their preparation and use: US20090209588A1; 2009
96. Novo Nordisk A/S. Novel compounds, their preparation and use: US20090012171A1; 2009
97. Novo Nordisk A/S; High Point Pharmaceuticals, LLC. Novel compounds, their preparation and use: US20110039841A1; 2011
98. High Point Pharmaceuticals, LLC. Phenoxy acetic acids as PPAR delta activators: US20110245244A1; 2011
99. Seoul National University Industry Foundation. Aryl compounds as PPAR ligands and their use: WO2008066356A1; 2008
100. SRI International. PPAR-delta ligands and methods of their use: US20090163481A1; 2009
101. Shionogi Co., Ltd.; Institute of medicinal molecular design. Derivative having PPAR agonistic activity: US20090286974A1; 2009
102. Kalypsys, Inc. Novel compounds as modulators of PPAR: US20080287477A1; 2008
103. Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as PPAR modulators for the treatment of non-alcoholic steatohepatitis: US20080176861A1; 2008
104. Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR: US20060205736A1; 2006
105. Kalypsys, Inc. Oral Pharmaceutical formulation compromising a sulfonyl bicyclic modulator of PPAR for the treatment of disease: WO2008043024A2; 2008
106. Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR: US20060167012A1; 2006
107. Teijin Ltd. Method for screening substance by measuring PPAR delta activating effect and agent: US20080287544A1; 2008
108. Toudai TLO, Ltd. Insuline secretagogue drugs: US20080207710A1; 2008
109. Cerenis Therapeutics S.A. Novel uses of PPAR delta agonists: WO2008154023A1; 2008
110. the University of Dundee. PPAR delta Inhibitors for treatment of cardiovascular diseases: EP1200114B1; 2009
111. University Court of the University of Dundee. Methods concerning PPAR delta and antagonists thereof: US20110263691A1; 2011
112. Shearer BG, Steger DJ, Way JM, et al. Identification and characterization of a selective peroxisome proliferator-activated receptor/(NR1C2) antagonist. Mol Endocrinol 2007;22(2):523-9
113. Noa Noy. Methods of treating metabolic disorders: US20090137671A1; 2009
114. Eli Lilly and Co. Peroxisome proliferator activated receptor modulators: WO2003072100; 2003
115. Seoul National University Foundation. Thiazole compound (as PPAR delta) ligand and pharmaceutical, cosmetic and health food comprised thereof: US20100041723A1; 2010
116. Sanofi-Aventis U.S. LLC. Cyclic N-[1,3,4].thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for the therapeutic use thereof: US20080280959A1; 2008
117. Sanofi-Aventis U.S. LLC. N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions thereof and methods for their therapeutic use: US20090054494A1; 2009
118. Sanofi-Aventis U.S. LLC. Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol- 2-ylamides, processes for their preparation, pharmaceutical compositions and methods for their use: US20100022603A1; 2010
119. Sanofi-Aventis Deutschland GmbH. Oxadizolones and derivatives thereof as peroxisome proliferator-activated receptor delta agonists: US7709509B2; 2010
120. Genomics Institute of the Novartis Research Foundation. Compounds and compositions as PPAR modulators: US20090192203A1; 2009
121. Eli Lilly and Co. Peroxisome proliferator activated receptor modulator: WO2008103574A3; 2008
122. Plexxikon, Inc. PPAR active compounds: US20080249137A1; 2008
123. Plexxikon, Inc. PPAR active compounds: US20080221127A1; 2008
124. Plexxikon, Inc. PPAR active compounds: WO2008109700A1; 2008
125. Ryu J-H. Alkoxy indole-3-acetic acid derivative acting as PPAR alpha/gamma/delta agonists, preparation method thereof, and pharmaceutical composition containing same as active ingredient: WO2011031111A2; 2011
126. Masson C. PPAR agonist compounds, preparation and uses: US20110195993A1; 2011